Our study adds further data to the growing evidence that adjuvant trastuzumab treatment is beneficial to the prognosis of HER2-positive pT1a-b pN0 breast cancer, but selected patients with hormone receptor positive tumors might benefit from endocrine therapy only. This evidence concerns the gene NR4A1 and breast carcinoma.